AR053662A1 - Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk - Google Patents

Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk

Info

Publication number
AR053662A1
AR053662A1 ARP060100202A ARP060100202A AR053662A1 AR 053662 A1 AR053662 A1 AR 053662A1 AR P060100202 A ARP060100202 A AR P060100202A AR P060100202 A ARP060100202 A AR P060100202A AR 053662 A1 AR053662 A1 AR 053662A1
Authority
AR
Argentina
Prior art keywords
cdk
quinasa
inhibitors
compounds inhibitors
activity
Prior art date
Application number
ARP060100202A
Other languages
English (en)
Spanish (es)
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0501480A external-priority patent/GB0501480D0/en
Priority claimed from GB0501748A external-priority patent/GB0501748D0/en
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of AR053662A1 publication Critical patent/AR053662A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
ARP060100202A 2005-01-21 2006-01-19 Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk AR053662A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US64621705P 2005-01-21 2005-01-21
GB0501480A GB0501480D0 (en) 2005-01-22 2005-01-22 Pharmaceutical compounds
GB0501748A GB0501748D0 (en) 2005-01-27 2005-01-27 Pharmaceutical compounds
US65133905P 2005-02-09 2005-02-09

Publications (1)

Publication Number Publication Date
AR053662A1 true AR053662A1 (es) 2007-05-16

Family

ID=35967182

Family Applications (3)

Application Number Title Priority Date Filing Date
ARP060100202A AR053662A1 (es) 2005-01-21 2006-01-19 Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
ARP060100205A AR052660A1 (es) 2005-01-21 2006-01-19 Derivados de pirazol para inhibir la cdk's y gsk's
ARP060100204A AR052559A1 (es) 2005-01-21 2006-01-19 Derivados de pirazol para inhibir cdk's y gsk's

Family Applications After (2)

Application Number Title Priority Date Filing Date
ARP060100205A AR052660A1 (es) 2005-01-21 2006-01-19 Derivados de pirazol para inhibir la cdk's y gsk's
ARP060100204A AR052559A1 (es) 2005-01-21 2006-01-19 Derivados de pirazol para inhibir cdk's y gsk's

Country Status (15)

Country Link
US (2) US20080194562A1 (enExample)
EP (3) EP1846395A1 (enExample)
JP (3) JP2008528466A (enExample)
KR (3) KR20070107049A (enExample)
AR (3) AR053662A1 (enExample)
AU (3) AU2006207313A1 (enExample)
BR (2) BRPI0606317A2 (enExample)
CA (3) CA2593465A1 (enExample)
IL (3) IL184503A0 (enExample)
MA (3) MA29255B1 (enExample)
MX (3) MX2007008780A (enExample)
NO (3) NO20073955L (enExample)
PE (3) PE20061198A1 (enExample)
TN (3) TNSN07278A1 (enExample)
WO (3) WO2006077419A1 (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1651612T3 (pl) 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
TW200533657A (en) 2004-02-17 2005-10-16 Esteve Labor Dr Substituted pyrazoline compounds, their preparation and use as medicaments
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR053662A1 (es) * 2005-01-21 2007-05-16 Astex Therapeutics Ltd Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
EP1845975A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
US20090036435A1 (en) * 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
EP1845974A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
JP5138220B2 (ja) * 2005-03-03 2013-02-06 三菱レイヨン株式会社 ポリマー粒子を含む樹脂組成物、成形体
EP1743892A1 (en) 2005-07-15 2007-01-17 Laboratorios del Dr. Esteve S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
US7897589B2 (en) 2005-07-15 2011-03-01 Laboratorios Del Dr. Esteve, S.A. Substituted pyrazoline compounds, their preparation and use as medicaments
EP1743890A1 (en) 2005-07-15 2007-01-17 Laboratorios Del Dr. Esteve, S.A. 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments
US20090318500A1 (en) * 2006-05-05 2009-12-24 Astex Therapeutics Limited 4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer
JP2009536186A (ja) * 2006-05-08 2009-10-08 アステックス・セラピューティクス・リミテッド 癌処置のためのジアゾール誘導体の医薬組合せ
US20100004243A1 (en) * 2006-07-14 2010-01-07 Astex Therapeutics Limited Pharmaceutical compounds
EP2046330A2 (en) * 2006-07-14 2009-04-15 Astex Therapeutics Limited Pharmaceutical combinations
WO2008009954A1 (en) * 2006-07-21 2008-01-24 Astex Therapeutics Limited Medical use of cyclin dependent kinases inhibitors
WO2008023720A1 (en) * 2006-08-23 2008-02-28 Astellas Pharma Inc. Urea compound or salt thereof
EP2073803B1 (en) 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
FR2908409B1 (fr) 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
FR2913018A1 (fr) * 2007-02-23 2008-08-29 Sanofi Aventis Sa Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
EP2267459A1 (en) * 2009-06-25 2010-12-29 Universite Pierre Et Marie Curie - Paris VI Method for determining the susceptibility of a cell strain to drugs
CA2834049C (en) * 2011-04-25 2018-05-22 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
DE102011106990B3 (de) * 2011-07-08 2013-01-03 Technische Universität Darmstadt Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen
BRPI1107312B1 (pt) 2011-11-25 2021-09-08 Universidade Federal De Santa Catarina Composto de acil-hidrazona
CN104093712B (zh) * 2012-02-21 2016-11-09 方济各安吉利克化学联合股份有限公司 作为糖原合酶激酶3β抑制剂的1H-吲唑-3-甲酰胺化合物
US20150099645A1 (en) * 2012-03-14 2015-04-09 Stephen Marx Means and methods for diagnostics and therapeutics of diseases
US8765762B2 (en) 2012-10-25 2014-07-01 Usher III, Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome
US9227976B2 (en) 2012-10-25 2016-01-05 Usher Iii Initiative, Inc. Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
ES2693166T3 (es) * 2012-10-25 2018-12-07 Usher Iii Initiative, Inc. Pirazolopiridina y métodos para tratar las enfermedades retinales degenerativas y la pérdida auditiva asociadas con el síndrome de Usher
KR20150095888A (ko) 2012-12-19 2015-08-21 노파르티스 아게 오토탁신 억제제
US9409895B2 (en) 2012-12-19 2016-08-09 Novartis Ag Autotaxin inhibitors
WO2014174846A1 (ja) 2013-04-25 2014-10-30 杏林製薬株式会社 固形医薬組成物
WO2014179144A1 (en) * 2013-04-29 2014-11-06 E. I. Du Pont De Nemours And Company Fungicidal heterocyclic compounds
EP2980088A1 (en) 2014-07-28 2016-02-03 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
WO2015113927A1 (en) * 2014-01-29 2015-08-06 Bayer Pharma Aktiengesellschaft Amino-substituted isothiazoles
CA2960279A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
HK1246645A1 (zh) 2015-03-27 2018-09-14 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
TWI730959B (zh) 2015-05-19 2021-06-21 英商葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之雜環醯胺
KR102470813B1 (ko) 2018-03-27 2022-11-28 다이킨 고교 가부시키가이샤 전해액, 전기 화학 디바이스, 리튬 이온 이차 전지 및 모듈
KR20230012099A (ko) 2018-03-27 2023-01-25 다이킨 고교 가부시키가이샤 술팜산리튬의 제조 방법 및 신규 술팜산리튬
HUE061383T2 (hu) 2018-03-27 2023-06-28 Daikin Ind Ltd Elektrolit oldat, elektrokémiai eszköz, lítium-ion másodlagos akkumulátor, modul és vegyület
CN112367991A (zh) * 2018-06-25 2021-02-12 达纳-法伯癌症研究所股份有限公司 Taire家族激酶抑制剂及其用途
EP3902542A4 (en) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 and uses thereof
CN111848579B (zh) 2019-04-26 2023-11-14 君实润佳(上海)医药科技有限公司 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
TW202320750A (zh) * 2021-10-25 2023-06-01 香港商優領醫藥科技(香港)有限公司 含四氫呋喃多環類衍生物、其藥學上可接受的鹽及其製備方法和應用
TW202337434A (zh) * 2022-02-11 2023-10-01 美商傳達治療有限公司 Ｃｄｋ抑制劑及其使用方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282361A (en) * 1978-03-16 1981-08-04 Massachusetts Institute Of Technology Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
WO1997027852A1 (en) * 1996-01-30 1997-08-07 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
AU2001241128A1 (en) * 2000-03-14 2001-09-24 Fujisawa Pharmaceutical Co. Ltd. Novel amide compounds
US6455559B1 (en) * 2001-07-19 2002-09-24 Pharmacia Italia S.P.A. Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents
US20050119305A1 (en) * 2001-03-21 2005-06-02 Masao Naka Il-6 production inhibitors
GB0218625D0 (en) * 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
US7169797B2 (en) * 2003-02-14 2007-01-30 Abbott Laboratories Protein-tyrosine phosphatase inhibitors and uses thereof
US7320989B2 (en) * 2003-02-28 2008-01-22 Encysive Pharmaceuticals, Inc. Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists
TWI372050B (en) * 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
PL1651612T3 (pl) * 2003-07-22 2012-09-28 Astex Therapeutics Ltd Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3)
AR053662A1 (es) * 2005-01-21 2007-05-16 Astex Therapeutics Ltd Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
US20090036435A1 (en) * 2005-01-21 2009-02-05 Astex Therapeutics Limited Pharmaceutical Compounds
EP1845975A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
EP1845974A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
AR054425A1 (es) * 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
US20080139620A1 (en) * 2005-01-21 2008-06-12 Astex Therapeutics Limited Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's

Also Published As

Publication number Publication date
NO20073960L (no) 2007-09-24
PE20061198A1 (es) 2006-12-19
BRPI0606107A2 (pt) 2009-06-02
NO20073955L (no) 2007-09-24
NO20073956L (no) 2007-10-22
KR20070098928A (ko) 2007-10-05
AU2006207316A1 (en) 2006-07-27
PE20061073A1 (es) 2006-11-29
IL184499A0 (en) 2007-10-31
IL184503A0 (en) 2007-10-31
WO2006077416A1 (en) 2006-07-27
IL184502A0 (en) 2007-10-31
WO2006077419A1 (en) 2006-07-27
MA29255B1 (fr) 2008-02-01
BRPI0606317A2 (pt) 2009-06-16
US20080194562A1 (en) 2008-08-14
JP2008528466A (ja) 2008-07-31
MX2007008782A (es) 2007-09-11
US20080306069A1 (en) 2008-12-11
EP1853584A1 (en) 2007-11-14
MA29253B1 (fr) 2008-02-01
TNSN07279A1 (en) 2008-12-31
CA2593465A1 (en) 2006-07-27
CA2593468A1 (en) 2006-07-27
JP2008528467A (ja) 2008-07-31
MA29254B1 (fr) 2008-02-01
CA2593656A1 (en) 2006-07-27
JP2008528465A (ja) 2008-07-31
AR052559A1 (es) 2007-03-21
WO2006077414A1 (en) 2006-07-27
TNSN07278A1 (en) 2008-12-31
MX2007008784A (es) 2007-09-11
KR20070107049A (ko) 2007-11-06
PE20060876A1 (es) 2006-10-16
MX2007008780A (es) 2007-09-11
EP1853600A1 (en) 2007-11-14
EP1846395A1 (en) 2007-10-24
KR20070098927A (ko) 2007-10-05
TNSN07281A1 (en) 2008-12-31
AR052660A1 (es) 2007-03-28
AU2006207313A1 (en) 2006-07-27
AU2006207311A1 (en) 2006-07-27

Similar Documents

Publication Publication Date Title
AR053662A1 (es) Compuestos de pirazol inhibidores de la actividad quinasa cdk y gsk
ATE469154T1 (de) Pyrazolopyrimidine als zellzyklus-kinasehemmer
CR20120053A (es) Compuestos y metodos inhibidores de jak de pirazolopirimidina
TW200611907A (en) Fused heterocyclic compound
ATE508747T1 (de) C-kit kinase-hemmer
ECSP045229A (es) Piridinonas sustituidas como moduladores de la p38 map quinasa
TW200744604A (en) P38 MAP kinase inhibitors and methods for using the same
EA200200802A1 (ru) 5-АЛКИЛПИРИДО[2.3-d]ПИРИМИДИНОВЫЕ ИНГИБИТОРЫ ТИРОЗИНКИНАЗЫ
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
NO20070731L (no) Heterocykliske forbindelser.
NZ599040A (en) 2,4-disubstituted pyrido[4,3-d]pyrimidin-5(6h)-one compounds for selective inhibitors of lrrk2 and syk kinases
DE60309848D1 (de) Purinderivate als kinaseinhibitoren
CU23834B1 (es) Compuestos de pirazolo [3,4-d] pirimidinona y sus derivados para la inhibición pde9
TW200740815A (en) P38 MAP kinase inhibitors and methods for using the same
NO20070532L (no) Substituerte 2-alkyl-kinazolinonderivater som PARP-inhibitorer
BRPI0814065B8 (pt) derivados de alcoóis de 1-fenil-2-piridinil alquila como inibidores da fosfodiesterase
NO20075987L (no) Bisykliske derviater som p38-kinaseinhibitorer
ATE479667T1 (de) Als kinaseinhibitoren geeignete verbindungen auf thiazolylbasis
GB0100889D0 (en) Compounds
BR0213140A (pt) Fungicidas de pirazol-pirimidina
UY31750A (es) Compuestos y composiciones como inhibidores de quinasa
MX2009012885A (es) Nuevo derivado de 1,2,3,4-tetrahidroquinoxalina que tiene, como sustituyente, grupo fenilo que tiene estructura de ester de acido sulfonico o estructura de amida de acido sulfonico introducida en este, y tiene actividad de enlace al receptor de gluco
TW200740805A (en) Novel compounds
NO20076345L (no) Bisykliske derivater som P38-kinaseinhibitorer
AR047531A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal